Accretion Pharmaceuticals Limited (NSE:ACCPL)

Market Cap	905.40M
Revenue (ttm)	826.43M +329.7%
Net Income	90.81M
EPS	9.82
Shares Out	11.12M
PE Ratio	8.29
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	46,800
Average Volume	20,580
Open	81.70
Previous Close	77.85
Day's Range	77.05 - 81.70
52-Week Range	53.80 - 102.50
Beta	n/a
RSI	66.02
Earnings Date	Jun 10, 2026

About Accretion Pharmaceuticals

Accretion Pharmaceuticals Limited engages in the manufacturing and marketing of pharmaceutical products in India. The company offers antibiotic, antibacterial, antifungal, anti-inflammatory, anti-spasmodic, antihistamine, antiallergy, anticough, anticold, antiulcer, gastrointestinal, antacid, anti-diabetic, cardiac, anti-hypertensive, psychotropic, memory enhancer, vitamins, supplements, and other products. It also provides external preparation, oral powder, effervescent formulation, and nutraceutical products, as well as formulations for brain...

• Industry: Pharmaceutical Preparations
• Founded: 2012
• Employees: 125
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: ACCPL

Financial Performance

In fiscal year 2025, Accretion Pharmaceuticals's revenue was 573.76 million, an increase of 329.70% compared to the previous year's 133.53 million. Earnings were 67.94 million, an increase of 355.08%.